Penile Enhancement Procedures: A Complete Evidence-Based Guide

What Actually Works, What to Avoid, and the P-Long Protocol Explained
Curated By Nelson Vergel | ExcelMale.com | Updated March 2026​

Introduction: Separating Evidence from Hype in Male Enhancement​

Have you ever wondered whether any penile enhancement procedure actually works — and more importantly, whether it’s safe? If you’ve done even a cursory online search, you’ve encountered a bewildering mix of surgical procedures, injectable fillers, traction devices, and exotic supplements, each promising dramatic results. The reality, as supported by the most rigorous clinical guidelines available today, is considerably more nuanced — and more hopeful than the fringe treatments of the past.

Concerns about penile size are far more common than most men admit. Studies consistently show that a significant percentage of men — even those with normal or above-average anatomy — report dissatisfaction with their size. This psychological dimension is critical to understand before pursuing any procedure. In fact, the 2024 Sexual Medicine Society of North America (SMSNA) Position Statement on cosmetic penile enhancement makes clear that screening for body dysmorphic disorder and penile dysmorphic disorder must occur before any invasive treatment is considered.

The good news is that the field has genuinely evolved. We now have formal clinical guidelines, emerging non-surgical protocols with actual peer-reviewed data, and a clearer map of what procedures carry unacceptable risks. This guide synthesizes the 2024 SMSNA position statement, the peer-reviewed P-Long Study data, clinical evidence on penile traction therapy and injectable fillers, and real-world insights from the ExcelMale community. By the end, you will understand which options are supported by evidence, which carry serious risks, and what questions to ask before proceeding with any enhancement approach.

Understanding the Clinical Landscape: Why Most Men Overestimate the Problem​

Before evaluating any procedure, it is worth establishing what ‘normal’ actually means. Research published in the British Journal of Urology International based on data from over 15,000 men established that the average erect penile length is approximately 5.16 inches (13.12 cm) and the average erect girth is approximately 4.59 inches (11.66 cm). Men seeking enhancement often fall well within the normal range, a fact that should always be part of the clinical discussion.

The SMSNA explicitly acknowledges that many men seeking enhancement procedures have normative anatomy. This is one reason why psychological screening — including assessment for penile dysmorphic disorder, a subtype of body dysmorphic disorder — is not optional. Body dysmorphic disorder is characterized by a preoccupation with a perceived defect in appearance that causes significant distress, and it is an absolute contraindication to cosmetic surgery in most medical contexts.

The ExcelMale community, with its 20-plus years of real-world discussions, has long recognized this dynamic. Forum members frequently remind each other that optimization — whether hormonal, functional, or psychological — is best pursued from a foundation of realistic expectations and accurate information. The most effective intervention for some men is not a procedure at all, but a better understanding of their own anatomy and the psychological factors at play.

A Clinical Taxonomy of Penile Enhancement Procedures​

Not all enhancement procedures are equal in their evidence base, invasiveness, or risk profile. The SMSNA 2024 position statement evaluated five major categories of invasive enhancement: injectable soft tissue fillers, suspensory ligament division, graft-and-flap surgical procedures, silicone sleeve implants, and sliding/slicing techniques. Understanding how these categories differ is essential for any informed decision.

Injectable Soft Tissue Fillers​

Injectable fillers represent the least invasive surgical category. The most studied options are hyaluronic acid (HA) and polylactic acid (PLA). These temporary agents work by occupying volume in the areolar space between the Dartos and Buck’s fasciae. HA fillers have a distinct safety advantage: they are fully reversible with the enzyme hyaluronidase, which can dissolve the filler almost immediately if complications arise.

The SMSNA notes that limited data suggest potential cosmetic girth benefits from HA and PLA fillers, typically in the range of 1.5–2.5 cm of additional circumference, with an acceptable short-term safety profile. Retrospective data presented at the 2024 American Urological Association meeting on nearly 500 patients showed that complications were minor and manageable, with very low rates of infection or granuloma formation when procedures were performed by trained practitioners.

The critical caveat: HA fillers are temporary, often dissipating within six months in penile tissue due to its high metabolic activity and mechanical demands. Repeated treatments are typically necessary to maintain results. Additionally, “shifting” or migration of the gel can cause uneven appearance.
What the SMSNA says: HA and PLA fillers may be offered by experienced clinicians under IRB-approved protocols. The SMSNA urges formal safety and efficacy analyses before widespread adoption.
In sharp contrast, permanent fillers — including paraffin and liquid silicone — are strongly contraindicated by the SMSNA. These materials have a well-documented history of severe long-term complications, including tissue necrosis, progressive inflammatory pain, chronic swelling, and permanent deformities requiring complex reconstructive surgery involving grafts and flaps. The ExcelMale forum has documented numerous cases of men requiring multiple surgeries to address complications from unregulated filler procedures, underscoring why this recommendation is not merely theoretical.

Calcium Hydroxylapatite (CaHA) and Polycaprolactone (PCL) Fillers​

Two additional injectable categories — calcium hydroxylapatite (CaHA, sold as Radiesse) and polycaprolactone (PCL, sold as Ellané) — occupy a middle ground. Rather than simply adding volume, these agents act as collagen stimulators: their microspheres (approximately 25–50 micrometers in diameter) trigger the body’s own fibroblasts to produce new collagen around the material, creating a “live implant” effect.

CaHA is firmer than HA and lasts longer, typically over one year, but carries a specific risk of granulation and palpable nodularity when volumes exceed approximately 12 cc across multiple sessions. PCL is increasingly used in non-US markets with high patient satisfaction reported for firmness and longevity (one to three years depending on formulation). Neither is reversible, which increases the stakes if results are unsatisfactory or complications develop.

These agents have limited published data specifically for penile use compared with HA, and the SMSNA’s guidance appropriately reflects that uncertainty.

Suspensory Ligament Division (SLR)​

Suspensory ligament division (SLR) involves surgically cutting the ligament that anchors the base of the penis to the pubic bone. The theory is that releasing this tether will allow more of the internal penile shaft to protrude, increasing flaccid length. The SMSNA acknowledges that in the hands of experienced surgeons, SLR may produce modest increases in flaccid length, averaging approximately 2.5 cm (roughly one inch).

However, the trade-offs are significant. The suspensory ligament provides structural support during erection, and its division can result in penile instability during intercourse, loss of the normal erection angle, sensory changes, and in some cases erectile dysfunction. Additionally, many men find that the scar tissue that forms during healing partially reattaches the ligament, diminishing gains over time.

Bottom line: SLR may be appropriate for a narrow subset of patients after extensive counseling, but only when performed by high-volume surgeons and only after the patient fully understands the risk of reduced erection stability and potential functional loss.

Silicone Sleeve Implants (Penuma/Himplant)​

Silicone sleeve devices — most prominently the Penuma and Himplant — are medical-grade silicone implants placed subcutaneously over the tunica albuginea to increase flaccid and erect girth. These are the most aggressive non-prosthetic augmentation options currently available.

The SMSNA takes a firm position: these devices should be considered investigational and performed only under IRB oversight, without cost to the patient, and exclusively by experienced surgeons following comprehensive informed consent. Reported explantation (removal) rates range from 3 to 11 percent, most commonly due to infection, chronic pain, or patient dissatisfaction. A 2025 publication in the Journal of Sexual Medicine specifically documented complication profiles following Penuma removal, highlighting the surgical complexity involved.

From a strategic long-term perspective, a critically important consideration is future surgical access. If a younger man pursues a silicone sleeve procedure and later develops erectile dysfunction requiring an inflatable penile prosthesis (IPP), the presence of extensive subcutaneous scarring can make IPP insertion technically far more challenging or potentially impossible. Clinicians counsel patients to preserve their “future surgical options” by exhausting less-invasive approaches first.

Graft-and-Flap Procedures and Sliding/Slicing Techniques​

These represent the most invasive and highest-risk end of the spectrum. Graft-and-flap procedures use autologous dermal fat or allograft material to augment length or girth. Sliding and slicing techniques involve tunical incisions to release corporal length. The SMSNA recommends against both categories for cosmetic augmentation outside of research protocols, noting their procedural complexity, absence of external validation, and potential for “disastrous complications” in the language of the 2024 guidelines. These procedures should only be performed by expert prosthetic surgeons within IRB-supervised settings.

Evidence Summary: Cosmetic Penile Enhancement Procedures​

The following table summarizes the five major categories evaluated by the 2024 SMSNA Position Statement:

Procedure	Target Outcome	Evidence Level	SMSNA Recommendation
Injectable HA/PLA Fillers	Erect/Flaccid Girth	Limited but acceptable safety data	May be offered under IRB protocols
Permanent Fillers (Paraffin/Silicone)	Girth	Serious adverse events documented	Strongly contraindicated
Suspensory Ligament Division	Flaccid Length	Modest evidence, risk of instability	Select patients, experienced surgeons only
Silicone Sleeve Implants (Penuma)	Flaccid/Erect Girth	Limited long-term data; 3–11% explant rate	Investigational; IRB oversight required
Graft-and-Flap / Slicing	Length and Girth	High complication risk, no validation	Recommended against outside research
P-Long Protocol (PRP + Traction + VED + NO)	Erect Length and Girth	Prospective pilot study; zero adverse events	Investigational; promising evidence base

The P-Long Protocol: A Non-Surgical Multi-Modal Approach​

Among the emerging approaches to penile enhancement, the P-Long Protocol — developed by board-certified urologist Dr. Judson Brandeis in collaboration with Dr. Charles Runels — represents the most thoroughly studied non-surgical option to date. Published data from the P-Long Study (Brandeis et al., 2023), presented at the International Society of Sexual Medicine meeting and subsequently published in the journal Andrology, offers the first IRB-approved, prospective evidence for a multi-component, non-invasive enhancement protocol.

The Four Pillars of the P-Long Protocol​

The protocol’s philosophy is what researchers call therapeutic stacking: combining compatible interventions that address different physiological mechanisms, producing cumulative results that exceed any single intervention. The four components are:

• Pillar 1 – Platelet-Rich Plasma (PRP): Autologous PRP is prepared using a double-spin centrifuge technique (PurePRP PS60 system, 3.8 x 10³ rpm) that achieves a 6.6- to 6.7-fold platelet concentration compared to whole blood. A 60 cc blood draw yields 10 cc of PRP containing approximately 1.65 billion platelets, which is injected bilaterally into the corpora cavernosa under ultrasound guidance (5 cc per side, infused slowly over 2 minutes per corpus). Monthly injections are administered for six months. PRP delivers concentrated growth factors that stimulate vascular smooth muscle regeneration and endothelial health, essentially “priming” the tissue for mechanical expansion.

• Pillar 2 – Penile Traction Therapy (RestoreX): The RestoreX device (developed in cooperation with the Mayo Clinic) is used for 20 minutes twice daily in the straight position to maximize longitudinal tension. Unlike legacy traction devices requiring 3–8 hours daily, the RestoreX delivers equivalent or superior results in 30–40 minutes, dramatically improving patient compliance. The mechanism is mechanotransduction: sustained tension converts into cellular proliferation signals, triggering new tissue synthesis. A separate randomized controlled trial (Ziegelmann et al.) demonstrated that RestoreX achieves mean length gains of approximately 1.5 cm in just three months in men with Peyronie’s disease.

• Pillar 3 – Vacuum Erection Device (VED): A vacuum erection device (Dr. Joel Kaplan pump) is used twice daily in an interval training format: two one-minute cycles followed by two five-minute cycles, maintaining 5–10 mmHg of negative pressure. This VED protocol is not used for erectile assistance but as a “vascular gym” — repeatedly cycling tumescence to expand the corpora cavernosa laterally and condition the surrounding fascia and skin, promoting girth enhancement.

• Pillar 4 – Nitric Oxide Supplementation (AFFIRM): Daily supplementation with 3 grams of L-Citrulline (a potent NO precursor) and 1 gram of standardized beet root extract (4:1 concentrate), along with Muira Puama and Panax Ginseng extracts. This is split across two doses (morning and evening) to maintain steady-state bioavailability. Nitric oxide optimizes vascular smooth muscle function, supporting the increased blood flow demands of the mechanical phases.

P-Long Study Results​

The pilot study enrolled 29 healthy men aged 20–55 with normal baseline erectile function (mean SHIM score 24–25/25) and no penile pathology. Mean baseline erect length was 5.70 inches and mean baseline girth was 5.25 inches.

After six months of the full protocol, results were:

• Mean erect length increase: 0.805 inches (15.2% from baseline), paired t-test p = 0.000
• Mean erect girth increase: 0.469 inches (9.1% from baseline), paired t-test p = 0.000
• Erectile function: 100% of participants reported improvement on a 5-point Likert scale
• Adverse events: Zero — no ecchymosis, hematoma, pain, or sensory loss reported

A particularly meaningful finding for patient counseling: men with a baseline erect length at or below 5.40 inches experienced a 21.0% mean length increase, roughly double the 10.4% gain seen in men with baseline lengths above 5.40 inches. This suggests the protocol may have its greatest impact in men who have more to gain.

The study authors also noted that the growth curve had not plateaued at six months, suggesting that continued treatment may yield additional results. This contrasts with the typical diminishing returns seen with many injectable filler approaches.

Important Limitations to Acknowledge​

In keeping with ExcelMale’s commitment to intellectual honesty about evidence, it is important to note several limitations of the current P-Long data. The study enrolled only 29 participants, which is a small sample by clinical trial standards. Penile measurements were performed using standardized at-home photography rather than clinician-performed measurements, which introduces some measurement variability. The study design was non-randomized without a control group, meaning we cannot fully account for placebo effects or observer bias.

Larger, controlled, multi-institutional trials are needed to confirm these findings. The SMSNA’s broader position — that most non-surgical enhancement protocols remain investigational — applies here as well, despite the promising early data. That said, the P-Long protocol’s safety profile is exceptional: the interventions involved (PRP injections, mechanical devices, oral supplements) have well-established safety records individually, and their combination in this study produced zero adverse events.

Penile Traction Therapy: The Evidence for Length Enhancement​

Outside of the P-Long protocol context, penile traction therapy (PTT) has the most robust clinical evidence of any non-surgical enhancement approach. Multiple randomized controlled trials have evaluated PTT for Peyronie’s disease — a condition characterized by penile curvature and scarring — and the length data from these trials is directly relevant to healthy men.

The landmark Ziegelmann et al. randomized controlled trial, conducted at the Mayo Clinic and published in the Journal of Sexual Medicine, enrolled men with Peyronie’s disease using RestoreX for 30–90 minutes per day over three months. At three months, the traction group demonstrated statistically significant improvements compared to controls in length (mean gain of 1.5 cm vs. 0 cm, p < 0.001), penile curvature, and erectile function among men with baseline erectile dysfunction. Critically, 94% of PTT participants experienced increased penile length, and no significant adverse events were reported.

The mechanism — mechanotransduction — is well established in other areas of medicine. Controlled mechanical tension triggers cellular signaling cascades that promote tissue proliferation and remodeling. The innovation of the RestoreX device is its ability to deliver high-intensity tension in a short time window (20–40 minutes daily), rather than the 3–8 hours required by traditional traction devices, making compliance far more achievable.

For men specifically interested in length enhancement without surgical risk, PTT with the RestoreX device represents the most evidence-supported starting point. The combination of traction with PRP and vacuum therapy — as in the P-Long protocol — may further amplify results through complementary mechanisms.

The Psychological Dimension: What Every Man Should Know Before Pursuing Enhancement​

The SMSNA, European Association of Urology, and American Urological Association are unanimous on one point: psychological screening is mandatory before any invasive enhancement procedure. This is not a formality — it is clinically essential.

Research consistently shows that men who are deeply dissatisfied with their size often fall within the normal anatomical range. When that dissatisfaction is driven by body dysmorphic disorder or penile dysmorphic disorder, no surgical procedure will produce lasting satisfaction. Multiple case series document men who underwent successful enhancement procedures by objective measures, yet remained equally or more distressed afterward.

Before pursuing any enhancement procedure, consider these questions honestly:

• Do you fall within the normal size range (erect length approximately 4.7–6.3 inches)?
• Is your concern primarily about how your partner perceives you, or your own perception?
• Have multiple partners expressed concerns, or is this an internal narrative?
• Would you still be interested in enhancement if it carried a 10% risk of worsened erectile function?
• Have you discussed this with a mental health professional or a qualified sexual medicine physician?

The ExcelMale community provides a non-judgmental space where men ask these questions openly. The consistent wisdom from experienced members is that addressing the psychological component — whether through therapy, better communication with partners, or simply understanding the data on normal size distributions — often produces more satisfaction than a procedure ever could.

Patient Selection and Pre-Procedural Evaluation​

For men who have undergone psychological evaluation and still wish to pursue enhancement, proper pre-procedural screening significantly impacts both safety and outcomes. The P-Long protocol’s inclusion criteria provide a useful framework:

• Age 20–55 years
• Baseline erectile function within normal range (SHIM score approximately 24–25)
• No history of Peyronie’s disease or active penile pathology
• No prior penile surgery, implants, or permanent filler injections
• No significant uncontrolled medical conditions (e.g., severe cardiovascular disease, uncontrolled diabetes)
• Penile dysmorphic disorder ruled out

For injectable filler procedures, additional preparation includes reviewing current medications (anticoagulants increase bleeding risk), discussing realistic expectations about duration of results, and confirming that the procedure will be performed by a urologist or sexual medicine specialist rather than a general aesthetic provider. The SMSNA’s perspective on provider capabilities is clear: management of potential complications — including compartment syndrome or vascular injury — requires urological surgical training that many aesthetic providers lack.

Practical Guidance for ExcelMale Members​

Based on the current evidence landscape, here is a practical framework for men exploring enhancement options:

Starting Point: Non-Invasive Options​

For any man interested in enhancement, beginning with non-invasive, reversible approaches carries the lowest risk and preserves all future options:

• Penile traction therapy (RestoreX): The best-evidenced non-surgical option for length. Requires commitment (20 minutes twice daily) but produces meaningful gains in men with both normal anatomy and Peyronie’s disease.
• Vacuum erection device (VED): Used in an interval protocol (not simply for single-session use), VED contributes to girth conditioning and has established penile rehabilitation benefits.
• Nitric oxide support: L-Citrulline (3 g daily) and standardized beet root extract support vascular health and may improve erectile quality independently, with an excellent safety profile.

For Men Considering Injectable Fillers​

If you have ruled out body dysmorphic disorder, fall within normal anatomy, and still desire girth enhancement, injectable HA fillers represent the most appropriate first-line invasive option:

• Seek a board-certified urologist or sexual medicine specialist — not a general aesthetics provider
• Ensure the procedure is conducted within a formal protocol with informed consent documenting realistic expectations
• Start with the minimum volume necessary (typically 5–10 cc) to assess results before additional sessions
• Confirm hyaluronidase reversal capability is immediately available in case of complications
• Avoid any provider offering permanent fillers, silicone, or paraffin — these are contraindicated regardless of how they are marketed

For Men Considering Surgical Options​

Surgical enhancement should be a last resort pursued only after exhausting non-invasive and minimally invasive options, with full awareness of risks:
• Suspensory ligament division: Only in select patients with realistic expectations about flaccid (not erect) length gains, and only with an experienced urological surgeon who clearly explains the risks to erection stability.
• Silicone sleeve implants: Currently investigational. Only appropriate within IRB-supervised clinical trials, without cost to the patient, by experienced surgeons.
• Avoid: Any clinic offering sliding/slicing techniques or graft-and-flap procedures for cosmetic enhancement outside of a research protocol.

A Note on Unregulated Providers​

The ExcelMale community has long documented the risks of unregulated or unqualified providers offering penile enhancement services. Men have sought care after receiving unauthorized filler injections at medspas or unregulated clinics, sometimes resulting in infections, permanent scarring, or functional impairment. The principle here is straightforward: if a procedure modifies your anatomy permanently, only a qualified sexual medicine specialist or urologist should perform it. The stakes of error are too high, and the complexity of complications too great, for any other approach.

Related ExcelMale Forum Discussions​

Explore these community discussions for additional insights:
• Cosmetic Penile Enhancement Procedures: SMSNA Position Statement — Comprehensive coverage of the 2024 SMSNA position statement, including all six position statements on injectable fillers, ligament division, silicone implants, and experimental techniques.
• RestoreX Penile Traction Device: Development and Advantages — Video discussion with Dr. Trost on why RestoreX was developed at the Mayo Clinic, its clinical advantages over legacy devices, and trial results.
• Outcomes of RestoreX in Men with Peyronie's Disease: Randomized Trial — Full summary of the Ziegelmann et al. randomized controlled trial showing length and curvature improvements with RestoreX in just three months.
• Innovations in Penile Traction: The Comfort Grip and Comfort Bend — Discussion of new RestoreX accessories that improve compliance and comfort during penile traction therapy.
• Increase Penile Length? What ACTUALLY Works (Dr. Morgentaler Explains) — Dr. Morgentaler and Dr. Brandon discuss the evidence behind various penile enhancement procedures, including risks and the importance of working with qualified specialists.
• Penile Enlargement: Filling with Hyaluronic Acid — Where Are We? — Presentation by Dr. Tardelli on HA fillers as a minimally invasive approach, including historical context and technical considerations.
• Insight into Removal of the Penuma/Himplant Device — Surgical technique for Penuma removal; illustrates the complexity involved when silicone sleeve implants require explantation.
• The Current State of Male Genital Cosmetic Procedures — Video journal presentation from ISSM on the evolving landscape of male genital cosmetic procedures, including the most current clinical perspectives.

Key References​

• Trost L, Watter DN, Carrier S, Khera M, et al. Cosmetic penile enhancement procedures: an SMSNA position statement. Journal of Sexual Medicine. 2024;21(6):573–578. [Link]
• Brandeis J, Lu S, Malik R, Runels C. Increasing penile length and girth in healthy men using a novel protocol: The P-Long Study. Andrology. 2023;12:293. [Link]
• Brandeis J, Lu S, Runels C. A pilot study of a novel PRP protocol to increase penile length, girth, and function. Journal of Sexual Medicine. 2024;21(Suppl 1). [Link]
• Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device (RestoreX) in men with Peyronie’s disease: a randomized, single-blinded, controlled trial. Journal of Sexual Medicine. 2019. [Link]
• Pearlman A, Gumpf K, Moore W, et al. Safety of novel hyaluronic acid dermal filler injections for penile girth enhancement. AUA Annual Meeting. 2024. [Link]
• Fernandez Crespo RE, Parker J, Carrion R. Complications and management of penile enhancement procedures. Translational Andrology and Urology. 2025;14(10):3367–3376. [Link]
• Barham DW, Lee J, et al. Complications of the Penuma penile implant for genital enhancement. Journal of Sexual Medicine. 2025;22:975–977.
• Falagario UG, Piramide F, Pang KH, et al. Techniques for penile augmentation surgery: a systematic review of surgical outcomes, complications, and quality of life. Medicina (Kaunas). 2024;60(5):758.
• Falcone M, Bettocchi C, Carvalho J, et al. European Association of Urology guidelines on penile size abnormalities and dysmorphophobia: summary of the 2023 guidelines. European Urology Focus. 2024;10(3):432–441.
• Veale D, Miles S, Bramley S, et al. Am I normal? A systematic review and construction of nomograms for flaccid and erect penis length and circumference in up to 15,521 men. BJUI. 2015;115(6):978–986.

Medical Disclaimer​

This article is provided for educational and informational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Penile enhancement procedures carry significant risks, including permanent functional impairment, scarring, infection, and disfigurement. Any man considering these procedures should consult with a board-certified urologist or sexual medicine specialist. The information presented here reflects the state of the medical literature as of early 2026 and is subject to change as new research emerges. ExcelMale.com and Nelson Vergel are not responsible for decisions made based on this content.

About ExcelMale​

ExcelMale.com is the internet’s leading men’s health forum, with over 24,000 members and more than 20 years of archived discussions on testosterone replacement therapy, hormone optimization, sexual health, peptides, and men’s wellness. Founded by Nelson Vergel — a long-term patient advocate, author, and educator in men’s hormonal health — ExcelMale bridges peer-reviewed clinical evidence with the real-world experiences of men navigating complex health decisions.
Nelson Vergel is the author of Testosterone: A Man’s Guide and Beyond Testosterone, books that have helped thousands of men understand and optimize their hormonal health. His advocacy work, which began in the 1990s when testosterone therapy helped address a serious personal health challenge, has made ExcelMale a trusted resource for patients and clinicians alike.
Join the ExcelMale community at www.ExcelMale.com.

 

One of ExcelMale sponsors:

Male Enhancement Services - Penile Dermal Fillers - GetMoreGirth

GetMoreGirth is a leading provider of male enhancement services, utilizing FDA-approved dermal fillers for the specific needs of clients!

getmoregirth.com